NEO212, temozolomide conjugated to perillyl alcohol, is a novel drug for effective treatment of a broad range of temozolomide-resistant gliomas

Molecular Cancer Therapeutics

Volumn 13, Issue 8, 2014, Pages 2004-2017

  Cho, Hee Yeon ^a   Wang, Weijun ^a   Jhaveri, Niyati ^a   Lee, David Jungpa ^a   Sharma, Natasha ^a   Dubeau, Louis ^a   Schönthal, Axel H ^b   Hofman, Florence M ^a   Chen, Thomas C ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NEO 212; PERILLYL ALCOHOL; TEMOZOLOMIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DACARBAZINE; DNA METHYLTRANSFERASE; MGMT PROTEIN, HUMAN; NEO212; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPHAGY; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG CONJUGATION; DRUG CYTOTOXICITY; ENDOPLASMIC RETICULUM STRESS; EXCISION REPAIR; GENE OVEREXPRESSION; GLIOMA; GLIOMA CELL LINE; HUMAN; HUMAN CELL; IN VIVO STUDY; INTRACRANIAL TUMOR; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; APOPTOSIS; BRAIN NEOPLASMS; DNA DAMAGE; DRUG RESISTANCE; DRUG SCREENING; METABOLISM; NUDE MOUSE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BRAIN NEOPLASMS; CELL LINE, TUMOR; DACARBAZINE; DNA DAMAGE; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DRUG RESISTANCE, NEOPLASM; GLIOMA; HUMANS; MICE, NUDE; TUMOR SUPPRESSOR PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84905663623     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0964     Document Type: Article

References (49)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96. (Pubitemid 40349501)
2. Weller M, Cloughesy T, Perry JR, Wick W. Standards of care for treatment of recurrent glioblastoma - are we there yet? Neuro Oncol 2013;15:4-27.
3. Holland EC. Glioblastoma multiforme: the terminator. Proc Natl Acad Sci U S A 2000;97:6242-4. (Pubitemid 30412695)
4. Fuller CD, Choi M, Forthuber B, Wang SJ, Rajagiriyil N, Salter BJ, et al. Standard fractionation intensity modulated radiation therapy (IMRT) of primary and recurrent glioblastoma multiforme. Radiat Oncol 2007;2:26.
5. Cho HY, Wang W, Jhaveri N, Torres S, Tseng J, Leong MN, et al. Perillyl alcohol for the treatment of temozolomide-resistant gliomas. Mol Cancer Ther 2012;11:2462-72.
6. Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clin Cancer Res 2000;6:2585-97. (Pubitemid 30482092)
7. Stupp R, Hegi ME, van den Bent MJ, Mason WP, Weller M, Mirimanoff RO, et al. Changing paradigms-an update on the multidisciplinary management of malignant glioma. Oncologist 2006;11:165-80. (Pubitemid 43261763)
8. Dehdashti AR, Hegi ME, Regli L, Pica A, Stupp R. New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy. Neurosurg Focus 2006;20:E6.
9. Wiseman DA, Werner SR, Crowell PL. Cell cycle arrest by the isoprenoids perillyl alcohol, geraniol, and farnesol is mediated by p21 (Cip1) and p27(Kip1) in human pancreatic adenocarcinoma cells. J Pharmacol Exp Ther 2007;320:1163-70. (Pubitemid 46294051)
10. Bailey HH, Attia S, Love RR, Fass T, Chappell R, Tutsch K, et al. Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer. Cancer Chemother Pharmacol 2008;62:149-57. (Pubitemid 351537855)
11. Yeruva L, Pierre KJ, Elegbede A, Wang RC, Carper SW. Perillyl alcohol and perillic acid induced cell cycle arrest and apoptosis in non small cell lung cancer cells. Cancer Lett 2007;257:216-26. (Pubitemid 47538829)
12. Lanevskij K, Japertas P, Didziapetris R. Improving the prediction of drug disposition in the brain. Expert Opin Drug Metab Toxicol 2013;9:473-86.
13. Darkes MJM, Plosker GL, Jarvis B. Temozolomide a reviewof its use in the treatment of malignant gliomas, malignant melanoma and other advanced cancers. Am J Cancer 2002;1:55-80. (Pubitemid 36835016)
14. Fukushima T, Takeshima H, Kataoka H. Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT. Anticancer Res 2009;29:4845-54.
15. Weller M, Stupp R, Reifenberger G, Brandes AA, van den Bent MJ, Wick W, et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol 2010;6:39-51.
16. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003. (Pubitemid 40349502)
17. Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 2008;26:4189-99.
18. Fu D, Calvo JA, Samson LD. Balancing repair and tolerance of DNA damagecaused by alkylating agents. Nat Rev Cancer 2012;12:104-20.
19. Cahill DP, Levine KK, Betensky RA, Codd PJ, Romany CA, Reavie LB, et al. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res 2007;13:2038-45. (Pubitemid 46649870)
20. Zhang J, Stevens MF, Laughton CA, Madhusudan S, Bradshaw TD. Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications. Oncology 2010;78:103-14.
21. Curtin NJ, Wang LZ, Yiakouvaki A, Kyle S, Arris CA, Canan-Koch S, et al. Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells. Clin Cancer Res 2004;10:881-9. (Pubitemid 38198886)
22. Trivedi RN, Almeida KH, Fornsaglio JL, Schamus S, Sobol RW. The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death. Cancer Res 2005;65:6394-400. (Pubitemid 40994427)
23. Johannessen TC, Bjerkvig R. Molecular mechanisms of temozolomide resistance in glioblastoma multiforme. Expert Rev Anticancer Ther 2012;12:635-42.
24. Tang JB, Goellner EM, Wang XH, Trivedi RN, St Croix CM, Jelezcova E, et al. Bioenergetic metabolites regulate base excision repair-dependent cell death in response to DNA damage. Mol Cancer Res 2010;8:67-79.
25. Jhaveri N, Cho H, Torres S, Wang W, Schonthal AH, Petasis NA, et al. Noscapine inhibits tumor growth in TMZ-resistant gliomas. Cancer Lett 2011;312:245-52.
26. Virrey JJ, Guan S, Li W, Schonthal AH, Chen TC, Hofman FM. Increased survivin expression confers chemoresistance to tumor-associated endothelial cells. Am J Pathol 2008;173:575-85.
27. Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Ruschoff J, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004;96:261-8. (Pubitemid 38256271)
28. Virrey JJ, Golden EB, Sivakumar W, Wang W, Pen L, Schonthal AH, et al. Glioma-associated endothelial cells are chemoresistant to temozolomide. J Neuro Oncol 2009;95:13-22.
29. Collins AR. The comet assay for DNA damage and repair: principles, applications, and limitations. Mol Biotechnol 2004;26:249-61. (Pubitemid 41490465)
30. Zhou BB, Bartek J. Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat Rev Cancer 2004;4:216-25. (Pubitemid 38337501)
31. Lin CJ, Lee CC, Shih YL, Lin CH, Wang SH, Chen TH, et al. Inhibition of mitochondria- and endoplasmic reticulum stress-mediated autophagy augments temozolomide-induced apoptosis in glioma cells. PLoS One 2012;7:e38706.
32. Deegan S, Saveljeva S, Gorman AM, Samali A. Stress-induced self-cannibalism: on the regulation of autophagy by endoplasmic reticulum stress. Cell Mol Life Sci 2013;70:2425-41.
33. Sarkaria JN, Kitange GJ, James CD, Plummer R, Calvert H, Weller M, et al. Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin Cancer Res 2008;14:2900-8.
34. Pitz MW, Desai A, Grossman SA, Blakeley JO. Tissue concentration of systemically administered antineoplastic agents in human brain tumors. J Neuro Oncol 2011;104:629-38.
35. Rosso L, Brock CS, Gallo JM, Saleem A, Price PM, Turkheimer FE, et al. A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients. Cancer Res 2009;69:120-7.
36. McCullough KD, Martindale JL, Klotz LO, Aw TY, Holbrook NJ. Gadd153 sensitizes cells to endoplasmic reticulum stress by down-regulating Bcl2 and perturbing the cellular redox state. Mol Cell Biol 2001;21:1249-59. (Pubitemid 32114973)
37. Puthalakath H, O'Reilly LA, Gunn P, Lee L, Kelly PN, Huntington ND, et al. ER stress triggers apoptosis by activating BH3-only protein Bim. Cell 2007;129:1337-49. (Pubitemid 46962086)
38. Rubinsztein DC. Autophagy: where next? EMBO Rep 2010;11:3.
39. Kroemer G, Marino G, Levine B. Autophagy and the integrated stress response. Mol Cell 2010;40:280-93.
40. Kirkin V, McEwan DG, Novak I, Dikic I. A role for ubiquitin in selective autophagy. Mol Cell 2009;34:259-69.
41. Thomas S, Sharma N, Golden EB, Cho H, Agarwal P, Gaffney KJ, et al. Preferential killing of triple-negative breast cancer cells in vitro and in vivo when pharmacological aggravators of endoplasmic reticulum stress are combined with autophagy inhibitors. Cancer Lett 2012;325:63-71.
42. Ronellenfitsch MW, Steinbach JP, Wick W. Epidermal growth factor receptor and mammalian target of rapamycin as therapeutic targets in malignant glioma: current clinical status and perspectives. Target Oncol 2010;5:183-91.
43. Lo HW. Targeting Ras-RAF-ERK and its interactive pathways as a novel therapy for malignant gliomas. Curr Cancer Drug Targets 2010;10:840-8.
44. Le Calve B, Rynkowski M, Le Mercier M, Bruyere C, Lonez C, Gras T, et al. Long-term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression. Neoplasia 2010;12:727-39.
45. Sathornsumetee S, Rich JN. New treatment strategies for malignant gliomas. Expert Rev Anticancer Ther 2006;6:1087-104. (Pubitemid 44203386)
46. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000;343:1350-4.
47. Hunter C, Smith R, Cahill DP, Stephens P, Stevens C, Teague J, et al. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res 2006;66:3987-91.
48. Yip S, Miao J, Cahill DP, Iafrate AJ, Aldape K, Nutt CL, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin Cancer Res 2009;15:4622-9.
49. De Fazio S, Russo E, Ammendola M, Donato Di Paola E, De Sarro G. Efficacy and safety of bevacizumab in glioblastomas. Curr Med Chem 2012;19:972-81.